Plasma Neutrophil Gelatinase-Associated Lipocalin (2-0) Index: A Precise and Sensitive Predictor of Acute Kidney Injury in Children Undergoing Cardiopulmonary Bypass.

OBJECTIVE: To detect the efficacy of neutrophil gelatinase-associated lipocalin (NGAL) in the early prediction of acute kidney injury (AKI) in children undergoing cardiopulmonary bypass (CPB). METHODS: A prospective observational study was conducted wherein 174 patients, aged 6 to 60 months, with congenital heart disease, undergoing CPB and who had a normal baseline renal function were enrolled. Plasma NGAL measurement was done preoperatively and serially at 2, 12, 24, 36, and 48 hours post-CPB initiation. Patients were classified into 2 groups according to the development of postoperative AKI. RESULTS: Plasma NGAL levels post-CPB were significantly higher in the AKI group compared to the non-AKI group with positive significant correlations between plasma NGAL level and severity of AKI. A rise in plasma NGAL of 500% from its preoperative basal level, when measured at 2 hours post-CPB initiation (NGAL 2-0 index), showed sensitivity and specificity of 83% and 64%, respectively (AUC = 0.667) and at 12 hours post-CPB initiation (NGAL 12-0 index) showed sensitivity and specificity of 66% and 64% respectively (AUC = 0.762). CONCLUSION: Plasma NGAL is a predictive biomarker for acute kidney injury after pediatric cardiac surgery. A 500% rise in plasma NGAL at 2 hours post-CPB initiation from its basal preoperative level (NGAL 2-0 index) is a precise, sensitive, and early predictor of AKI in children.

Polyether ether ketone coated with nanohydroxyapatite/graphene oxide composite promotes bioactivity and antibacterial activity at the surface of the material.

Polyether ether ketone (PEEK) is considered an alternative material for manufacturing dental implants. However, PEEK lacks bioactivity and antibacterial action. In a series of experiments designed to enhance the surface properties of PEEK, we present a nanohydroxyapatite (nHA) and graphene oxide (GO) composite as a coating for PEEK-based dental implants to improve biological properties and antibacterial action. PEEK discs were polished, cleaned, and coated with the composite consisting of nHA particles doped with 0.75 wt% graphene oxide by a micro-emulsion technique according to patent US8,206,813. X-ray diffraction, field emission scanning electron microscopy-energy dispersive spectroscopy, and atomic force microscopy were utilized to characterize the composite coating. The wettability of the coated and non-coated samples was assessed by optical contact angle measurement. Antibacterial action of the composite coating was explored against S. aureus and E. coli and cytotoxicity determined utilizing osteoblast-like cells and gingival fibroblasts. The findings showed that the nHA/GO composite coating, approximately 1.3 µm thick, was homogenous with few micro-cracks and adhered to the PEEK surface. The surface roughness was reduced to 21.26 nm and the wettability was improved to 54.6° after coating with the composite coating. Antibacterial activity was moderate, killing 99% of S. aureus and E. coli, with acceptable levels of cytotoxicity to mammalian osteoblast-like cells and gingival fibroblasts.

A novel bioactive glass/graphene oxide composite coating for a polyether ether ketone-based dental implant.

Polyether ether ketone (PEEK) is a biocompatible material that lacks antimicrobial activity and bioactivity; therefore, is not appropriate for use as a dental implant. To overcome these deficiencies, a novel composite coating of bioactive glass and graphene oxide was prepared. PEEK discs were polished, cleaned, and the surface treated with sulfuric acid for 15 min. The composite coating consisted of bioactive glass produced by the sol-gel route and doped with 0.75 wt% graphene oxide. X-ray diffraction, Fourier transform infrared spectroscopy, and scanning electron microscopy-energy dispersive spectroscopy analyses were employed to characterize the composite coating, and the coating adhesion strength quantified using a pull-off test. Cytotoxicity was assessed using osteoblast-like cells and gingival fibroblasts. The wettability of the coated and non-coated samples was determined by optical contact angle assessment, and bioactivity was assessed by immersion in simulated body fluid. The results revealed that the bioactive glass/graphene oxide composite coating, approximately 7 µm thick, was transparent, homogenous with few microcracks and microporosities, but adhered strongly and was not cytotoxic to either osteoblast-like cells or gingival fibroblasts. The wettability of the PEEK sample was increased to <20° after coating with the composite, and apatite formation was detectable after 14 days of immersion in simulated body fluid.

Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Naïve Children without and with Comorbidities.

BACKGROUND: Chronic hepatitis C virus (HCV) infection represents a crucial health problem in children that greatly influences their quality of life. Many efforts have been directed toward investing in effective drugs with a high safety profile and oral administration for better compliance. OBJECTIVES: This study aims to assess the safety of a fixed-dose combination of ledipasvir/sofosbuvir plus drug efficacy and sustained virologic response (SVR) at 12 weeks after treatment discontinuation. METHOD: One tablet (90 mg ledipasvir, 400 mg sofosbuvir) was administered to treatment-naïve children aged 12-18 years weighing at least 35 kg with chronic HCV infection for 6 months, genotype 4. Patients were divided into 2 groups, (1) without comorbidities (24 patients) and (2) with comorbidities (26 patients). RESULTS: At the end of the therapy, all patients (100%) had SVR and a significant reduction of liver enzymes with mild tolerable side effects. CONCLUSION: Ledipasvir/sofosbuvir fixed-dose combination is a safe and highly effective therapeutic option in Egyptian children aged ≥ 12 years, with chronic HCV infection, genotype 4, either without or with comorbidities.

MgF2- containing glasses as a coating for titanium dental implant. I- Glass powder.

Bioactive glasses can be used to coat titanium implants to promote osseointegration. However, incorporating elements such as magnesium, zinc and fluoride into bioactive glasses might have a negative effect on bioactivity or the coefficient of thermal expansion of the glass. In this study, the impact of substituting MgO for CaO on physical properties and bioactivity of glass containing 1 mol % MgF2 was assessed. Seven glasses were produced by melt-quenched route. The glasses comprise (SiO2, CaO, Na2O, MgO, MgF2, K2O and P2O5) and were characterized utilizing XRD, DSC, FTIR and dilatometry analyses. The bioactivity of these glasses was investigated in biological fluids. The results showed that these glasses have wide sintering windows, low TECs and low glass transition and softening temperatures. The bioactive glasses containing up to 13.3 mol% MgO were able to form surface apatite within a short time period; whereas glasses containing ≥16.13 mol% demonstrated only structural variations with no clear sign of apatite precipitation.

Pyogenic granuloma: Clinicopathological and treatment scenario.

BACKGROUND: Oral pyogenic granuloma is a soft-tissue lesion of the oral mucosa. This lesion has a tendency to reoccur after surgical excision. MATERIALS AND METHODS: A total of 28 patients underwent surgical excision of pyogenic granuloma in the period from September 2014 to May 2016. Two surgical techniques were used to remove pyogenic granuloma: simple excision with root planing and modified excision with deep curettage. RESULTS: Females (54%) were slightly more predominant than males (46%). The upper and lower jaws were almost equally affected by the lesion with more predilection toward the posterior region. The size of the lesion ranged from 0.5 to 3 cm in diameter with slow-growing rate. Rural residents were more affected (57%) than urban people. The lesion appears clinically as a small red mass with sessile base, and these clinical features were similar in pregnant and nonpregnant women. The recurrence rate was 14.8% and seen only in patients treated by simple excision. Histopathological feature was consistent with inflammatory hyperplastic lesion, and there was no radiographic evidence of bone resorption associated with the lesion. CONCLUSION: Modified excision with deep curettage prevents the recurrence of the lesion after 1-year follow-up.

Angiotensin-converting enzyme gene insertion/deletion polymorphism in Egyptian patients with myocardial infarction.

INTRODUCTION: This work aimed to test the association of the angiotensin-converting enzyme gene insertion/deletion (I/D) polymorphism with myocardial infarction. SUBJECTS AND METHODS: This study comprised 79 Egyptian myocardial infarction cases with a mean age of 54.4+/-9.9 years including 60 males and 19 females, plus 238 healthy unrelated individuals of nearly matched age and sex as a control group. For all subjects, DNA testing for the angiotensin-converting enzyme gene I/D polymorphism was done using PCR amplification for detection of both the D and I alleles followed by a second run PCR specific for the I allele for samples typed as DD in the first run. RESULTS: Cases had a higher frequency of DD (29.1%) and ID (62.0%) genotypes than II (8.9%) genotype, with a higher frequency of D allele than I allele (64.4% vs. 33.6%). Compared to controls, cases had a significantly higher frequency of ID genotype (62.0% vs. 47.5%, p<0.05).This was more apparent among cases in the low risk group (p=0.002) than in the high risk group (p=0.041). CONCLUSION: The angiotensin-converting enzyme gene I/D polymorphism is probably a risk factor for ischaemic heart disease among Egyptian cases, particularly if integrated with other environmental and genetic risk factors.